JPMorgan Chase & Co. Purchases 95,547 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

JPMorgan Chase & Co. grew its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 212.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 140,491 shares of the company's stock after acquiring an additional 95,547 shares during the period. JPMorgan Chase & Co. owned 0.22% of Kymera Therapeutics worth $6,649,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in KYMR. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Kymera Therapeutics by 27.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company's stock valued at $114,000 after acquiring an additional 504 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Kymera Therapeutics by 8.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company's stock valued at $534,000 after purchasing an additional 915 shares during the period. Values First Advisors Inc. acquired a new position in shares of Kymera Therapeutics during the 3rd quarter worth approximately $61,000. Arizona State Retirement System increased its holdings in shares of Kymera Therapeutics by 15.6% during the second quarter. Arizona State Retirement System now owns 12,830 shares of the company's stock worth $383,000 after purchasing an additional 1,730 shares during the period. Finally, Handelsbanken Fonder AB raised its position in shares of Kymera Therapeutics by 12.3% in the third quarter. Handelsbanken Fonder AB now owns 17,300 shares of the company's stock valued at $819,000 after buying an additional 1,900 shares in the last quarter.

Wall Street Analyst Weigh In

KYMR has been the topic of a number of analyst reports. Wells Fargo & Company raised Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $38.00 to $57.00 in a research report on Monday, December 2nd. Guggenheim increased their target price on Kymera Therapeutics from $45.00 to $52.00 and gave the stock a "buy" rating in a report on Friday, November 1st. BMO Capital Markets began coverage on Kymera Therapeutics in a research note on Friday, December 6th. They issued a "market perform" rating and a $55.00 price target for the company. Truist Financial reiterated a "buy" rating and set a $53.00 price objective (down from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. Finally, Oppenheimer boosted their target price on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the company an "outperform" rating in a research report on Friday, September 27th. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $55.38.

Kymera Therapeutics Stock Down 7.2 %

Shares of KYMR stock traded down $3.13 during mid-day trading on Thursday, reaching $40.43. 754,055 shares of the stock traded hands, compared to its average volume of 573,279. The company has a market cap of $2.62 billion, a price-to-earnings ratio of -17.28 and a beta of 2.19. The stock's fifty day simple moving average is $43.45 and its two-hundred day simple moving average is $44.25. Kymera Therapeutics, Inc. has a 1-year low of $26.34 and a 1-year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $3.74 million for the quarter, compared to the consensus estimate of $10.34 million. During the same period last year, the company earned ($0.90) EPS. The firm's revenue was down 20.9% compared to the same quarter last year. On average, equities research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In other news, insider Ellen Chiniara sold 3,129 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $41.75, for a total value of $130,635.75. Following the completion of the sale, the insider now owns 54,826 shares of the company's stock, valued at approximately $2,288,985.50. This represents a 5.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 15.82% of the stock is owned by company insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.